Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy
dc.contributor.author | Arnold, Suzanne V. | |
dc.contributor.author | Li, Shu‐xia | |
dc.contributor.author | Alexander, Karen P. | |
dc.contributor.author | Spertus, John A. | |
dc.contributor.author | Nallamothu, Brahmajee K. | |
dc.contributor.author | Curtis, Jeptha P. | |
dc.contributor.author | Kosiborod, Mikhail | |
dc.contributor.author | Gupta, Aakriti | |
dc.contributor.author | Wang, Tracy Y. | |
dc.contributor.author | Lin, Haiqun | |
dc.contributor.author | Dharmarajan, Kumar | |
dc.contributor.author | Strait, Kelly M. | |
dc.contributor.author | Lowe, Timothy J. | |
dc.contributor.author | Krumholz, Harlan M. | |
dc.date.accessioned | 2017-11-13T16:41:31Z | |
dc.date.available | 2017-11-13T16:41:31Z | |
dc.date.issued | 2015-06 | |
dc.identifier.citation | Arnold, Suzanne V.; Li, Shu‐xia ; Alexander, Karen P.; Spertus, John A.; Nallamothu, Brahmajee K.; Curtis, Jeptha P.; Kosiborod, Mikhail; Gupta, Aakriti; Wang, Tracy Y.; Lin, Haiqun; Dharmarajan, Kumar; Strait, Kelly M.; Lowe, Timothy J.; Krumholz, Harlan M. (2015). "Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy." Journal of the American Heart Association (6): n/a-n/a. | |
dc.identifier.issn | 2047-9980 | |
dc.identifier.issn | 2047-9980 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/139118 | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | bleeding | |
dc.subject.other | variation | |
dc.subject.other | anticoagulation | |
dc.subject.other | myocardial infarction | |
dc.title | Hospital Variability in Use of Anticoagulant Strategies During Acute Myocardial Infarction Treated With an Early Invasive Strategy | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Cardiovascular Medicine | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/139118/1/jah31000.pdf | |
dc.identifier.doi | 10.1161/JAHA.115.002009 | |
dc.identifier.source | Journal of the American Heart Association | |
dc.identifier.citedreference | Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Mockel M, Caixeta A, Parise H, White H, Stone GW. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONSâ SWITCH analysis. J Am Coll Cardiol. 2011; 57: 2309 â 2316. | |
dc.identifier.citedreference | Steg PG, James SK, Atar D, Badano LP, Blomstromâ Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandezâ Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, vanâ t Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with STâ segment elevation. Eur Heart J. 2012; 33: 2569 â 2619. | |
dc.identifier.citedreference | Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent STâ segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent STâ segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2999 â 3054. | |
dc.identifier.citedreference | O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamisâ Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the management of STâ elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127: e362 â e425. | |
dc.identifier.citedreference | Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Jacobs AK. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/nonâ STâ elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 2022 â 2060. | |
dc.identifier.citedreference | Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and lowâ molecularâ weight heparin in acute coronary syndrome without ST elevation: a metaâ analysis. Lancet. 2000; 355: 1936 â 1942. | |
dc.identifier.citedreference | Sinnaeve PR, Simes J, Yusuf S, Garg J, Mehta S, Eikelboom J, Bittl JA, Serruys P, Topol EJ, Granger CB. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J. 2005; 26: 2396 â 2403. | |
dc.identifier.citedreference | Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ III, Califf RM. Highâ risk patients with acute coronary syndromes treated with lowâ molecularâ weight or unfractionated heparin: outcomes at 6Â months and 1Â year in the SYNERGY trial. JAMA. 2005; 294: 2594 â 2600. | |
dc.identifier.citedreference | Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial. Lancet. 2007; 369: 907 â 919. | |
dc.identifier.citedreference | Amin AP, Marso SP, Rao SV, Messenger J, Chan PS, House J, Kennedy K, Robertus K, Cohen DJ, Mahoney EM. Costâ effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. Circ Cardiovasc Qual Outcomes. 2010; 3: 358 â 365. | |
dc.identifier.citedreference | Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEATâ PPCI): an openâ label, single centre, randomised controlled trial. Lancet. 2014; 384: 1849 â 1858. | |
dc.identifier.citedreference | Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and state trends in quality of care for acute myocardial infarction between 1994â 1995 and 1998â 1999: the Medicare health care quality improvement program. Arch Intern Med. 2003; 163: 1430 â 1439. | |
dc.identifier.citedreference | Partovian C, Gleim SR, Mody PS, Li SX, Wang H, Strait KM, Allen LA, Lagu T, Normand SL, Krumholz HM. Hospital patterns of use of positive inotropic agents in patients with heart failure. J Am Coll Cardiol. 2012; 60: 1402 â 1409. | |
dc.identifier.citedreference | Safavi KC, Dharmarajan K, Kim N, Strait KM, Li SX, Chen SI, Lagu T, Krumholz HM. Variation exists in rates of admission to intensive care units for heart failure patients across hospitals in the United States. Circulation. 2013; 127: 923 â 929. | |
dc.identifier.citedreference | Premier Inc. Mission/Vision: What Premier Does. Retrieved from https://www.premierinc.com/about-premier/mission-and-vision. 2015. | |
dc.identifier.citedreference | Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010; 362: 2155 â 2165. | |
dc.identifier.citedreference | Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8 â 27. | |
dc.identifier.citedreference | Pinto DS, Ogbonnaya A, Sherman SA, Tung P, Normand SL. Bivalirudin therapy is associated with improved clinical and economic outcomes in STâ elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database. Circ Cardiovasc Qual Outcomes. 2012; 5: 52 â 61. | |
dc.identifier.citedreference | Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010; 31: 561 â 572. | |
dc.identifier.citedreference | Astroulakis Z, Hill JM. Does â switchingâ from heparin to bivalirudin monotherapy result in a bleeding benefit? Eur Heart J Suppl. 2009; 11: C13 â C18. | |
dc.identifier.citedreference | Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van’t Hof A, Guagliumi G, Hamm CW, Genereux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patientâ level analysis from the HORIZONSâ AMI and EUROMAX trials. J Am Coll Cardiol. 2015; 65: 27 â 38. | |
dc.identifier.citedreference | Grilli L, Rampichini C. A multilevel multinomial logit model for the analysis of graduatesâ skills. Stat Methods Appl. 2007; 16: 381 â 393. | |
dc.identifier.citedreference | Krumholz HM, Wang Y, Mattera JA, Han LF, Ingber MJ, Roman S, Normand SL. An administrative claims model suitable for profiling hospital performance based on 30â day mortality rates among patients with heart failure. Circulation. 2006; 113: 1693 â 1701. | |
dc.identifier.citedreference | Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015; 8: 414 â 423. | |
dc.identifier.citedreference | Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA. 2010; 303: 2156 â 2164. | |
dc.identifier.citedreference | Xian Y, Chen AY, Thomas L, Roe MT, Subherwal S, Cannon CP, Pollack CV Jr, Fonarow GC, Kosiborod M, Peterson ED, Alexander KP. Sources of hospitalâ level variation in major bleeding among patients with nonâ STâ segment elevation myocardial infarction: a report from the national cardiovascular data registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014; 7: 236 â 243. | |
dc.identifier.citedreference | Rao SC, Chhatriwalla AK, Kennedy KF, Decker CJ, Gialde E, Spertus JA, Marso SP. Preâ procedural estimate of individualized bleeding risk impacts physiciansâ utilization of bivalirudin during percutaneous coronary intervention. J Am Coll Cardiol. 2013; 61: 1847 â 1852. | |
dc.identifier.citedreference | Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR Action Registryâ GWTG (national cardiovascular data registry acute coronary treatment and intervention outcomes network registryâ get with the guidelines). JACC Cardiovasc Interv. 2010; 3: 1166 â 1177. | |
dc.identifier.citedreference | Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006; 118: 253 â 262. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.